pidotimod has been researched along with 2019 Novel Coronavirus Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jafrey, SZ; Karadkhele, A; Mahashur, A; Muchhala, S; Rathod, R; Suvarna, V; Vora, A; Waghray, P | 1 |
| Falasca, K; Moffa, L; Moffa, S; Ucciferri, C; Vecchiet, J | 1 |
| Al Basir, F; Chatterjee, AN | 1 |
3 other study(ies) available for pidotimod and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Expert Opinion on Usage of Pidotimod in Adult Patients with Chronic Obstructive Pulmonary Disease: An Indian Perspective.
Topics: Adult; COVID-19; Expert Testimony; Humans; Pulmonary Disease, Chronic Obstructive; Pyrrolidonecarboxylic Acid; SARS-CoV-2; Thiazolidines | 2021 |
Are monoclonal antibodies effective in patients with severe obesity in SARS-CoV-2 infected?
Topics: Antibodies, Monoclonal; Cholecalciferol; COVID-19; Humans; Obesity; Obesity, Morbid; SARS-CoV-2 | 2023 |
A Model for SARS-CoV-2 Infection with Treatment.
Topics: Adjuvants, Immunologic; Angiotensin-Converting Enzyme 2; Basic Reproduction Number; Betacoronavirus; Computer Simulation; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Dose-Response Relationship, Drug; Host Microbial Interactions; Humans; Mathematical Concepts; Models, Biological; Mutation; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Pyrrolidonecarboxylic Acid; Receptors, Virus; SARS-CoV-2; Spike Glycoprotein, Coronavirus; T-Lymphocytes, Cytotoxic; Thiazolidines | 2020 |